Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Akebia Therapeutics, Inc. (AKBA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
09/26/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Akebia Announces Approval of Vafseo® in Australia and Provides Commercial Update"
08/25/2023 8-K Quarterly results
Docs: "Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
08/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing"
08/11/2023 8-K Quarterly results
08/01/2023 8-K Quarterly results
07/18/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023"
06/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/07/2023 8-K Investor presentation
Docs: "Commercial Depth. Operational Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO June 2023 Exhibit 99.1"
06/02/2023 8-K Other Events  Interactive Data
05/31/2023 8-K Regulation FD Disclosure  Interactive Data
05/25/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia"
05/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"
05/09/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights"
05/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
04/28/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
03/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights"
03/02/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/09/2023 8-K Investor presentation
Docs: "Akebia Therapeutics, Inc. Presentation January 2023",
"Akebia Therapeutics, Inc. Presentation January 2023"
12/28/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Cost Associated with Exit or Disp...
12/15/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/07/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Open Market Sale AgreementSM, by and between Akebia Therapeutics, Inc. and Jefferies LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy